A new study by researchers at Brigham and Women’s Hospital in collaboration with researchers at Harvard T.H. Chan School of Public Health and the Brown School of Public Health, examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023.
This article was originally published on MedicalXpress.com
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
© 2024 SimplyWell.ca